When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ELOX - Dosing underway in mid-stage CF study of Proteostasis combo therapies
Eloxx Pharmaceuticals Inc.
The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' (PTI-1.6%) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous CF patients.
More news on: Proteostasis Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, AzurRx BioPharma, Inc., Healthcare stocks news,